As an inhibitor of Raf kinase, sorafenib inhibits tumor growth by decreasing the activities of the B-RAF serine/threonine kinase and RAF-111,12; concurrently, sorafenib can also inhibit tumor growth by decreasing tumor angiogenesis via the tyrosine kinase activities of platelet-derived growth factor (PDGF), FMS-like tyrosine kinase 3 (FLT-3), Vascular Endothelial Growth Factor 2 (VEGF-2), and -3 receptors13,14. Here, FLT3 is linked to neoplasm.